Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers

Journal of the National Cancer Institute

Volumn 91, Issue 3, 1999, Pages 259-263

  Lee, Jennifer S ^a,b   Wacholder, Sholom ^f   Struewing, Jeffery P ^f   McAdams, Mary ^c   Pee, David ^c   Brody, Lawrence C ^d   Tucker, Margaret A ^f   Hartge, Patricia ^e  

^a Medical Institute   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c INFORMATION MANAGEMENT SERVICES INC   (United States)

^d NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER SURVIVAL; COHORT ANALYSIS; FEMALE; FOLLOW UP; GENE DELETION; GENE INSERTION; HUMAN; HUMAN CELL; JEW; MAJOR CLINICAL STUDY; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; QUESTIONNAIRE; RELATIVE; SURVIVAL TIME;

EID: 0033518603     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.3.259     Document Type: Article

References (22)

1. Johannsson OT, Ranstam J, Borg A, Olsson H. Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol 1998;16: 397-404.
2. Verhoog LC, Brekelmans C, Seynaeve C, van den Bosch L, Dahmen G, van Geel AN, et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCAI. Lancet 1998;351:316-21.
3. Haas B, Robson M, Rajan P, Rosen PP, Borgen P, Brown K, et al. BRCA-associated breast cancer: absence of a characteristic immunophenotype [abstract 360]. Proceedings of the ASHG; 1997.
4. Robson M, Gilewski T, Haas B, Levine D, Lesser M, Borgen P, et al. BRCA-assodated breast cancer among young Jewish women [abstract 437A]. Proceedings of the ASHG; 1997.
5. Foulkes WD, Wong N, Brunei JS, Begin LR, Zhang JC, Martinez JJ, et al. Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. Clin Cancer Res 1997;3:2465-9.
6. Porter DE, Cohen BB, Wallace MR, Smyth E, Chetty U, Dixon JM, et al. Breast cancer incidence, penetrance and survival in probable carriers of BRCA1 gene mutation in families linked to BRCA1 on chromosome 17q12-21. Br J Surg 1994;81:1512-5.
7. Rubin SC, Benjamin I, Behbakht K, Takahashi H, Morgan MA, LiVolsi VA, et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 1996;335:1413-6.
8. Marcus JN, Watson P, Page DL, Narod SA, Lenoir GM, Tonin P, et al. Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 1996;77: 697-709.
9. Karp SE, Tonin PN, Begin LR, Martinez JJ, Zhang JC, Pollak MN, et al. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer 1997;80: 435-41.
10. Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 and BRCA2 mutations and sporadic cases. Lancet 1997;349:1505-10.
11. Eisinger F, Stoppa-Lyonnet D, Longy M, Kerangueven F, Noguchi T, Bailly C, et al. Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res 1996;56:471-4.
12. Struewing JP, Abeliovich D, Peretz T, Avishai N, Kaback MM, Collins FS, et al. The carrier frequency of the BRCA1185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals [published erratum appears in Nat Genet 1996;12:110]. Nat Genet 1995;11: 198-200.
13. Struewing JP, Abeliovich D, Peretz T, Avishai N, Kaback MM, Collins FS, et al. The carrier frequency of the BRCA1185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals [published erratum appears in Nat Genet 1996;12:110]. Nat Genet 1995;11: 198-200.
14. Oddoux C, Struewing JP, Clayton CM, Neuhausen S, Brody LC, Kaback M, et al. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1 %. Nat Genet 1996;14:188-90.
15. Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996;14:185-7.
16. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-8.
17. Kaplan EL, Meiev P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
18. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50: 163-70.
19. Wacholder S, Hartge P, Struewing JP, Pee D, McAdams M, Brody L, et al. The kin-cohort study for estimating penetrance. Am J Epidemiol 1998;148:623-30.
20. Wacholder S. Binomial regression in GLIM: estimating risk ratios and risk differences. Am J Epidemiol 1986;123:174-84.
21. Kerber RA, Slattery ML. Comparison of self-reported and database-linked family history of cancer data in a case-control study. Am J Epidemiol 1997;146:244-8.
22. Zhang H, Tombline G, Weber BL. BRCA1, BRCA2. and DNA damage response: collision or collusion? Cell 1998;92:433-6.